<span item_type="fundamental" item_id="2eef2a1de8fffe1c20bc8c187d8de7f9" counter_id="ST/US/BIAFW" env="prod"></span><span item_type="announcement" item_id="582796366721322881" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 1.446 M.</p><p>EPS: As of FY2025 Q3, the actual value is USD -4.74.</p><p>EBIT: As of FY2025 Q3, the actual value is USD -2.289 M.</p><p></p><h3>Segment Revenue</h3><ul><li><strong>Diagnostic R&amp;D</strong>: No revenue reported for the three months ended September 30, 2025, compared to $1,731 for the same period in 2024. For the nine months ended September 30, 2025, no revenue was reported compared to $8,654 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1712762/000149315225023405/form10-q.htm"></span></li><li><strong>Laboratory Services</strong>: Revenue of $1,446,066 for the three months ended September 30, 2025, compared to $2,348,655 for the same period in 2024. For the nine months ended September 30, 2025, revenue was $4,569,146 compared to $7,145,775 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1712762/000149315225023405/form10-q.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Net Loss</strong>: For the three months ended September 30, 2025, net loss was $5,051,084 compared to $2,000,840 in 2024. For the nine months ended September 30, 2025, net loss was $11,772,288 compared to $6,072,934 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1712762/000149315225023405/form10-q.htm"></span></li><li><strong>Operating Expenses</strong>: Total operating expenses for the three months ended September 30, 2025, were $3,738,912 compared to $4,324,250 in 2024. For the nine months ended September 30, 2025, operating expenses were $12,004,691 compared to $13,161,321 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1712762/000149315225023405/form10-q.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Net Cash Used in Operating Activities</strong>: - $6,769,279 for the nine months ended September 30, 2025, compared to - $5,587,634 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1712762/000149315225023405/form10-q.htm"></span></li><li><strong>Net Cash Used in Investing Activities</strong>: - $60,567 for the nine months ended September 30, 2025, compared to - $79,082 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1712762/000149315225023405/form10-q.htm"></span></li><li><strong>Net Cash Provided by Financing Activities</strong>: $13,393,750 for the nine months ended September 30, 2025, compared to $3,601,726 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1712762/000149315225023405/form10-q.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>CyPath® Lung Testing Revenue</strong>: Increased approximately 86% to $619,000 for the nine months ended September 30, 2025, compared to $332,000 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1712762/000149315225023405/form10-q.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: The company plans to expand commercialization of CyPath® Lung as an LDT under CAP/CLIA guidelines and regulations administered by CMS and CAP, and potentially expand sales in accordance with FDA rules and regulations if clearance is obtained.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1712762/000149315225023405/form10-q.htm"></span></li><li><strong>Non-Core Business</strong>: The company intends to seek strategic partners to develop therapeutic discoveries which could result in broad-spectrum cancer treatments in the future.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1712762/000149315225023405/form10-q.htm"></span></li></ul><h3>Priority</h3><ul><li>The company emphasizes the need to raise further capital through the sale of additional equity or debt securities or other debt instruments, strategic relationships or grants, or through exercised outstanding warrants to support future operations unless revenue increases significantly.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1712762/000149315225023405/form10-q.htm"></span></li></ul>

BIOAFFINITY TECHNOLOGIES INC C/WTS 07/09/2027 (TO PUR COM) | 10-Q: FY2025 Q3 Revenue: USD 1.446 M